SERDEXMETHYLPHENIDATE FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA

1 . A method of treating Idiopathic Hypersomnia in a patient, the method comprising:

administering to the patient in need thereof before bedtime a composition comprising a therapeutically effective amount of a conjugate of d-methylphenidate having a structure of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein the composition comprising the conjugate of d-methylphenidate is administered about 0-3 hours before the bedtime of the patient.

2 . The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, i-tartrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, and undecylenate.

3 . The method of claim 1 , wherein the conjugate of d-methylphenidate is serdexmethylphenidate chloride.

4 . The method of claim 1 , wherein the therapeutically effective amount of the conjugate of d-methylphenidate is between 0.1 mg and 500 mg per day.

5 . The method of claim 4 , wherein the therapeutically effective amount of the conjugate f d-methylphenidate is between 50 mg and 350 mg per day.

6 . The method of claim 5 , wherein the therapeutically effective amount of the conjugate f d-methylphenidate is selected from the group consisting of 80, 160, 240, or 320 mg per day.

7 . The method of claim 6 , wherein the therapeutically effective amount of the conjugate of d-methylphenidate is 240 mg per day.

8 . The method of claim 1 , wherein the therapeutically effective amount of a composition comprising serdexmethylphenidate chloride, wherein the therapeutically effective amount is selected from 87.5, 171.3, 257.0, or 342.7 mg per day.

9 . The method of claim 1 , wherein the composition comprising the conjugate of d-methylphenidate is administered once per day (QD).

10 . The method of claim 1 , wherein the Idiopathic Hypersomnia is associated with at least one additional sleep disorder selected from the group consisting of Excessive Daytime Sleepiness, Sleep Inertia, and Brain Fog.

11 . The method of claim 1 , wherein administering the composition comprising the conjugate of d-methylphenidate results in a decrease in at least one sleep disorder test score selected from the group consisting of Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Sleep Inertia Visual Analog Scale (SI-VAS), and Brain Fog Symptom Scale (BFS).

12 . The method of claim 11 , wherein the decrease in at least one sleep disorder test score is an at least 10% decrease in the Idiopathic Hypersomnia Severity Scale score.

13 . The method of claim 12 , wherein the at least 10% decrease in the Idiopathic Hypersomnia Severity scale is an at least 4 point decrease in the Idiopathic Hypersomnia Scale score.

14 . (canceled)

15 . (canceled)

16 . The method of claim 11 wherein the 10% decrease results in lowering the level of Idiopathic Hypersomnia severity.

17 . The method of claim 16 , wherein the patient in need thereof has a Idiopathic Hypersomnia Severity scale score of greater than 22 prior to starting the treatment.

18 - 22 . (canceled)

23 . The method of claim 1 , wherein the composition is an oral dosage formulation.

24 . (canceled)

25 . The method of claim 23 , wherein the oral dosage formulation is a solid dosage formulation selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a thin strip, an oral thin film (OTF), and an oral strip.

26 . (canceled)

27 . The method of claim 1 , wherein the composition comprises at least one additional active pharmaceutical ingredient.

28 . (canceled)

29 . A method of treating Excessive Daytime Sleepiness in a patient, the method comprising:

administering to the patient in need thereof before bedtime a composition comprising a therapeutically effective amount of a conjugate of d-methylphenidate having a structure of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein the composition comprising the conjugate of d-methylphenidate is administered about 0-3 hours before the bedtime of the patient.

30 .- 51 . (canceled)

52 . A method of treating Sleep Inertia in a patient, the method comprising:

administering to the patient in need thereof before bedtime a composition comprising a therapeutically effective amount of a conjugate of d-methylphenidate having a structure of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein the composition comprising the conjugate of d-methylphenidate is administered about 0-3 hours before the bedtime of the patient.

53 - 189 . (canceled)